Skip to content
value.today

Allergen Research Corp

Total raised
$335 M
3 rounds on record
Latest round
$98 M
Nov 2018
First round on record
Jan 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Allergen Research Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$98 MNo. 3$50 to $250 million

Allergen Research Corp: Raise no. 3, Nov 2018

Investors in this round

1 investor had bought by the notice of Nov 29, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Allergen Research Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$98 M of $98 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel C. Adelman · Executive Officer
  • Douglas T. Sheehy · Executive Officer
  • Eric H. Bjerkholt · Executive Officer
  • Jayson D.A. Dallas · Executive Officer, Director
  • Mary M. Rozenman · Executive Officer
  • Susan E. Barrowcliffe · Executive Officer
  • Brett K. Haumann · Director
  • Gregory E. Behar · Director
  • Kathryn E. Falberg · Director
  • Mark D. McDade · Director
  • Mark T. Iwicki · Director
  • Patrick G. Enright · Director
  • Stacey D. Seltzer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Patrick A. Pohlen, Assistant Secretary. Source: SEC Form D, newest notice filed Nov 29, 2018. Read the notice at the SEC.

equitySEC
Nov 2016$157 MNo. 2$50 to $250 million

Allergen Research Corp: Raise no. 2, Nov 2016

Investors in this round

2 investors had bought by the notice of Mar 16, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Allergen Research Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$157 M of $157 M offered
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel C. Adelman · Executive Officer
  • Douglas T. Sheehy · Executive Officer
  • Eric H. Bjerkholt · Executive Officer
  • Jeffrey H. Knapp · Executive Officer
  • Mary M. Rozenman · Executive Officer
  • Stephen G. Dilly, Jr. · Executive Officer, Director
  • Susan E. Barrowcliffe · Executive Officer
  • Gregory E. Behar · Director
  • Kathryn E. Falberg · Director
  • Mark D. McDade · Director
  • Mark T. Iwicki · Director
  • Patrick G. Enright · Director
  • Stacey D. Seltzer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Patrick A. Pohlen, Assistant Secretary. Source: SEC Form D, newest notice filed Mar 16, 2018. Read the notice at the SEC.

equitySEC
Jan 2015$80 MNo. 1$50 to $250 million

Allergen Research Corp: Raise no. 1, Jan 2015

Investors in this round

10 investors had bought by the notice of Mar 24, 2015: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Allergen Research Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen G. Dilly, Jr. · Executive Officer, Director
  • Victor G. Colunga · Executive Officer
  • Bryan L. Walser · Director
  • James D. Tananbaum · Director
  • Joonkyoo (Anthony) L. Yun · Director
  • Patrick G. Enright · Director
  • Stacey D. Seltzer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Patrick A. Pohlen, Secretary. Source: SEC Form D, newest notice filed Mar 24, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Allergen Research Corp chose not to state its revenue in its newest notice of a funding round (Nov 2018).

    SEC Form D · Nov 2018

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Nov 2018

That is all the official record says: Allergen Research Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website did not answer.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Allergen Research Corp
InvestorKindAmountRoundRoleSource
Foresite Capital Fund II, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Foresite Capital Management II, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Longitude Capital Partners II, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Longitude Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Allergen Research Corp
NameRoleNamed in
Daniel C. AdelmanExecutive officerNov 2018
Douglas T. SheehyExecutive officerNov 2018
Eric H. BjerkholtExecutive officerNov 2018
Jayson D.A. DallasExecutive officerNov 2018
Mary M. RozenmanExecutive officerNov 2018
Susan E. BarrowcliffeExecutive officerNov 2018
Jeffrey H. KnappExecutive officerMar 2018
Stephen G. Dilly, Jr.Executive officerMar 2018
Victor G. ColungaExecutive officerMar 2015
Brett K. HaumannDirectorNov 2018
Gregory E. BeharDirectorNov 2018
Jayson D.A. DallasDirectorNov 2018
Kathryn E. FalbergDirectorNov 2018
Mark D. McDadeDirectorNov 2018
Mark T. IwickiDirectorNov 2018
Patrick G. EnrightDirectorNov 2018
Stacey D. SeltzerDirectorNov 2018
Stephen G. Dilly, Jr.DirectorMar 2018
Bryan L. WalserDirectorMar 2015
James D. TananbaumDirectorMar 2015
Joonkyoo (Anthony) L. YunDirectorMar 2015

About

Company in London, United Kingdom.